EP2287156A1 — 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Assigned to IRM LLC · Expires 2011-02-23 · 15y expired
What this patent protects
Novel pyrimidine derivatives of formula (I) and their use for the manufacture of a medicament for the treatment or prevention of a disease which responds to inhibition of FAK and/or ALK and/or ZAP-70 and/or IGF-IR. in which: n' is selected from 1,2 and 3; R' 1 is selected …
USPTO Abstract
Novel pyrimidine derivatives of formula (I) and their use for the manufacture of a medicament for the treatment or prevention of a disease which responds to inhibition of FAK and/or ALK and/or ZAP-70 and/or IGF-IR. in which: n' is selected from 1,2 and 3; R' 1 is selected from phenyl, pyridinyl, pyrazolyl and pyrimidinyl; and R' 2 and R' 3 are as described herein.
Drugs covered by this patent
- Zykadia (ceritinib) · Novartis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.